Ajovy, a humanised monoclonal antibody that binds to calcitonin gene-related peptide ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine with quarterly (675 mg) and monthly (225 mg) dosing options.
Ajovy was evaluated in two Phase III, placebo-controlled clinical trials that enrolled patients with disabling migraine and was studied as both a stand-alone preventive treatment and in combination with oral preventive treatments.
In these trials, patients experienced a reduction in monthly migraine days during a 12-week period. The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.
The US Wholesale acquisition Cost of Ajovy is USD 575 per monthly dose and USD 1,725 per quarterly dose. Ajovy will be available through retail and specialty pharmacies in approximately two weeks.
There is a savings offer for Ajovy.
Commercially insured patients may pay as little as USD 0 on prescriptions for Ajovy until the offer expires.
Teva Shared Solutions is available to provide support services for patients and offices. Visit Ajovy.com to learn more.
Ajovy is indicated for the preventive treatment of migraine in adults. Ajovy is available as a 225 mg/1.5mL single dose injection in a prefilled syringe with two dosing options 225 mg monthly administered as one subcutaneous injection, or 675 mg every three months (quarterly), administered as three subcutaneous injections.
Ajovy can be administered in office by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment.
Contraindications: Ajovy is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with Ajovy in clinical trials.
Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration.
If a hypersensitivity reaction occurs, consider discontinuing Ajovy and institute appropriate therapy.
Adverse Reactions: The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.
Please for full Prescribing Information for Ajovy (fremanezumab-vfrm) injection.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) is a leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study